Back to Search

IAN FLINN, M.D.

M.D.

Hematology & Oncology Physician

NPI: 1417990367IndividualAccepts Medicare

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

41006(TN)

CMS Specialties

PrimaryHEMATOLOGY/ONCOLOGY

Education

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Class of 1990

Research & Publications (20)

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
PMID 17283364·J Clin Oncol·2007
3-trial
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.
PMID 19544775·Med Phys·2009
3-trial
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies.
PMID 18390348·IEEE Trans Med Imaging·2008
4-observational
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
PMID 17889355·Biol Blood Marrow Transplant·2007
2-rct
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
PMID 18220907·Curr Stem Cell Res Ther·2007
6-review
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
PMID 17671129·Clin Cancer Res·2007
3-trial
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
PMID 17283363·J Clin Oncol·2007
3-trial
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
PMID 17380530·Cancer·2007
3-trial
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
PMID 17438098·Clin Cancer Res·2007
8-other
Management of symptomatic, untreated chronic lymphocytic leukemia.
PMID 17097783·Blood Rev·2007
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
250 25TH AVE N, SUITE 412
NASHVILLE, TN 37203

Quick Facts

NPI
1417990367
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
36
Publications
20

Are you this provider?

Claim Your Profile